These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9260734)

  • 21. [Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2011; 45(6):825-37. PubMed ID: 22335126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
    Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
    J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients.
    Allan ER; Alpert M; Sison CE; Citrome L; Laury G; Berman I
    J Clin Psychiatry; 1996 Oct; 57(10):455-9. PubMed ID: 8909331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
    Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
    Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
    Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study.
    Smith RC; Chua JW; Lipetsker B; Bhattacharyya A
    J Clin Psychiatry; 1996 Oct; 57(10):460-6. PubMed ID: 8909332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychosocial functioning and health-related quality of life in children and adolescents treated with open-label ziprasidone for bipolar mania, schizophrenia, or schizoaffective disorder.
    Stewart M; DelBello MP; Versavel M; Keller D
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):635-40. PubMed ID: 20035581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.
    Owen RR; Gutierrez-Esteinou R; Hsiao J; Hadd K; Benkelfat C; Lawlor BA; Murphy DL; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):636-44. PubMed ID: 8343034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
    Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
    J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
    Müller MJ; Wetzel H; Eich FX; Rein W; Puech A; Benkert O;
    J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study].
    Romain JL; Dermain P; Greslé P; Grignon S; Moisan P; Nore D; Pech G; Benyaya J; Perret I
    Encephale; 1996; 22(4):280-6. PubMed ID: 9035983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement of depression and negative symptoms in schizophrenia.
    Goldman RS; Tandon R; Liberzon I; Greden JF
    Psychopathology; 1992; 25(1):49-56. PubMed ID: 1351305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents.
    Kumra S; Jacobsen LK; Lenane M; Karp BI; Frazier JA; Smith AK; Bedwell J; Lee P; Malanga CJ; Hamburger S; Rapoport JL
    J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):377-85. PubMed ID: 9549958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
    J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
    Díaz-Marsá M; Sánchez S; Rico-Villademoros F;
    J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjunctive trazodone in the treatment of negative symptoms of schizophrenia.
    Decina P; Mukherjee S; Bocola V; Saraceni F; Hadjichristos C; Scapicchio P
    Hosp Community Psychiatry; 1994 Dec; 45(12):1220-3. PubMed ID: 7868106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.